https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16940 −2 d1 + d15 q28) and oxaliplatin (100 mg m⁻² d2 + d16 q28) in induction (one cycle) and consolidation (three cycles), and 5FU 200 mg m⁻² per day over 6 weeks during 3DCRT 54 Gy. Results: Median duration of sustained local control (LC) was 15.8 months, progression-free survival (PFS) was 11.0 months, and overall survival was 15.7 months. Survival rates for 1, 2, and 3 years were 70.2%, 21.3%, and 12.8%, respectively. Global quality of life did not significantly decline from baseline during treatment, which was associated with modest treatment-related toxicity. Conclusion: Fixed-dose gemcitabine and oxaliplatin, combined with an effective and safe regimen of 5FU and 3DCRT radiotherapy, was feasible and reasonably tolerated. The observed improved duration of LC and PFS with more intensive therapy over previous trials may be due to patient selection, but suggest that further evaluation in phase III trials is warranted.]]> Wed 11 Apr 2018 15:02:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20435 Sat 24 Mar 2018 08:03:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18911 Sat 24 Mar 2018 08:03:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19644 n=29) or usual care control (n=28). Sexual activity was assessed by the European Organization for Research and Treatment of Cancer prostate cancer-specific quality of life questionnaire (QLQ-PR25). Results: QLQ-PR25 data were log transformed and analysis of covariance was used to compare sexual activity between groups following the intervention adjusted for baseline activity. No differences in sexual activity were observed between the exercise and control groups before the intervention. There was a significant (P=0.045) adjusted group difference in sexual activity following the 12-week intervention. Patients undergoing usual care decreased sexual activity while patients in the exercise program maintained their level of sexual activity. At baseline, 20.6 and 22.2% of participants in the exercise and control groups reported a major interest in sex (that is, high libido). Following the intervention, the exercise group had a significantly higher percentage of participants reporting a major interest in sex (exercise=17.2% vs control=0%; P=0.024). Conclusions: Participation in a short-term exercise program resulted in the maintenance of sexual activity in prostate cancer patients undergoing AST.]]> Sat 24 Mar 2018 08:01:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19546 Sat 24 Mar 2018 07:58:13 AEDT ]]>